Company Description
Actuate Therapeutics is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3).
We are developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3β.
We believe that the blockade of GSK-3β signaling ultimately results in the death of the cancer cells and the regulation of anti-tumor immunity.
We have exclusively licensed a portfolio of GSK-3 inhibitors developed in a collaboration between the University of Illinois-Chicago (UIC) and Northwestern University (NU).
The lead drug in our portfolio is called elraglusib (9-ING-41), which is being evaluated in a randomized Phase 2 trial in patients with metastatic pancreatic cancer, our most advanced clinical indication to date.
Country | United States |
Founded | 2015 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 10 |
CEO | Daniel Schmitt |
Contact Details
Address: 1751 River Run, Suite 400 Fort Worth, TX 76107 United States | |
Phone | (817) 887-8455 |
Website | actuatetherapeutics.com |
Stock Details
Ticker Symbol | ACTU |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001652935 |
Employer ID | 47-3044785 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Daniel M. Schmitt | President, Chief Executive Officer and Director |
Andrew P. Mazar, Ph.D. | Chief Operating Officer |
Paul Lytle | Chief Financial Officer |
Aaron G.L. Fletcher, Ph.D. | Chairperson and Director |
Les Kreis, Jr. | Director |
Todd Thomson | Director |
Dan Zabrowski, Ph.D. | Director |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 21, 2024 | FWP | Free Writing Prospectus |
Jun 21, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
Jun 20, 2024 | 8-A12B | Registration of securities |
Jun 11, 2024 | FWP | Free Writing Prospectus |
Jun 11, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
May 24, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
May 13, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
Apr 30, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
Apr 9, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
Mar 6, 2024 | D | Notice of Exempt Offering of Securities |